Amphastar Pharmaceuticals to Release Third Quarter Results and Hold a Conference Call on November 7, 2022



RANCHO CUCAMONGA, CA / ACCESS WIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its 2022 third quarter ended September 30, 2022, after market close on Monday, November 7, 2022, and will hold a conference call to discuss its financial results at 2:00 a.m. a.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference call.

The call is also available on the Investors page of the Company’s website.

Company information

Amphastar is a biopharmaceutical company primarily focused on the development, manufacturing, marketing and sale of technically challenging generic and proprietary injectable, inhalation and intranasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospitals or urgent care clinics and are mainly contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at

Forward-looking statements

All statements in this press release that are not historical are forward-looking statements. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may”, “could”, “will”, “could”, “should”, “should”, “anticipate”, “predict”, “potential”, “continue”, “expect” , “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements as they involve known and unknown risks, uncertainties and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control.Actual results may differ materially from those in the forward-looking statements due to a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 11, 2022. You can find these reports on the Company’s website at and on the SEC’s website at the address The forward-looking statements contained in this press release speak only as of the date of the press release. Amphastar undertakes no obligation to revise or update any information or forward-looking statements contained in this press release to reflect future events or circumstances, even if new information becomes available or if subsequent events change Amphastar’s expectations.

Bill Peters
Financial director
(909) 476-3416

THE SOURCE: Amphastar Pharmaceuticals, Inc.

See the source version on

Source link


Comments are closed.